ArriVent Pharmaceuticals Science
Programs
CandidateCand
IndicationInd
DiscoveryDisc
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
PartnersPart

Firmonertinib

Oral, brain penetrant, EGFR mutation selective inhibitor
NSCLC with EGFR Exon 20 insertion mutations
FURVENT
Furmo-004
NSCLC with EGFR Exon 20 insertion mutations
FURVENT
Furmo-004
Phase 3Ph 3
Allist logo
NSCLC with other EGFR mutations
FURTHER
Furmo-002
NSCLC with other EGFR mutations
FURTHER
Furmo-002
Phase 1bPh 1b
Allist logo
NSCLC with HER2 Exon 20 insertion mutations
FURTHER
Furmo-002
NSCLC with HER2 Exon 20 insertion mutations
FURTHER
Furmo-002
Phase 1bPh 1b
Allist logo

ARR-002

Antibody drug conjugate (ADC)
Solid Tumors
Solid Tumors
DiscoveryDisc
AARVIK logo

ARR-003

Antibody drug conjugate (ADC)
Solid Tumors
Solid Tumors
DiscoveryDisc

Firmonertinib

Mutational activation of the epidermal growth factor receptor (EGFR) is a common and early event in the development of non-small cell lung cancer (NSCLC) and confers oncogene dependency on the growth and proliferation of cancer cells. EGFR activating mutations are present in approximately 15% of NSCLC. Patients with NSCLC containing EGFR activating mutations are also particularly prone to the development of brain metastases, with 50% to 60% developing central nervous system (CNS) metastases over the course of their disease. Despite initial clinical response to currently approved EGFR inhibitors, patients with advanced EGFR mutated NSCLC inevitably acquire resistance mechanisms and progress at some point during treatment; therefore, there is the need for more effective, tolerable treatments.

Firmonertinib is an oral, highly brain-penetrant, broadly active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 insertion mutations. Firmonertinib is approved in China as an anticancer therapy for patients with NSCLC who have an EGFR T790M mutation, and more recently, as a first-line treatment in patients with NSCLC who have classical EGFR mutations. Firmonertinib is being developed in China by Allist Pharmaceuticals and in the rest of the world by ArriVent Biopharma.

ArriVent is studying firmonertinib globally in patients with NSCLC with EGFR mutations and HER2 Exon 20 insertion mutations.

ARR-002

We are partnered with Aarvik Therapeutics to advance a novel cancer therapeutic agent. As part of our agreement, Aarvik is responsible for the discovery and preclinical validation of the novel molecule, which is based on their unique modular platform that combines multiple target mechanisms. The ArriVent team will lead development and commercialization of the ARR-002 program.

ARR-003

We entered into a partnership with Alphamab Oncology for the discovery, development and commercialization of novel antibody drug conjugates (ADCs). The partnership will utilize the linker-payload platform and glycan-conjugation technology of Alphamab to identify promising ADC candidates for oncology indications. ArriVent has exclusive worldwide rights outside of the Greater China region for developing and commercializing the ADCs created through the partnership.